Ann: Immutep announces publication of ELCC 2022 abstract, page-14

I'm not able to add a link here for some reason, but you can find descriptions in tables online of course.

I've read them. there is conflicting descriptions and confusing terminology. I note the IMM relate ade talks about ORR in the context of 'objective response rate'.

In my primitive opinion the update is positive considering the the advanced disease at the starting point of treatment and the (poor prognosis) of the participants. We are looking at more than a third with haulted tumour growth or tumour shrinkage.

As we are becoming more aware of the slow but steadily improving responses and results over time with efti. I expect further updates to demonstrate greater efficacy. Let's see.